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Abstract
Background: It has been revealed that Staphylococcus aureus enterotoxin B (SEB) may feature anti-cancer and anti-metastatic ad-
vantages due to its ability to modify cell immunity processes and signaling pathways. Glioblastoma is one of the most aggressive
human cancers; it has a high mortality nature, which makes it an attractive area for the development of novel therapies.
Objectives: We examined whether the SEB could exert its growth inhibitory effects on glioblastoma cells partially through the
manipulation of a key tumor growth factor termed transforming growth factor-beta (TGF-β).
Materials and Methods: A human primary glioblastoma cell line, U87, was treated with different concentrations of SEB. The cell
quantity was measured by the MTT assay at different exposure times. For molecular assessments, total ribonucleic acid (RNA) was
extracted from either non-treated or SEB-treated cells. Subsequently, the gene expression of TGF-β transducers, smad2/3, at the mes-
senger RNA (mRNA) level, was analyzed via a quantitative real-time polymerase chain reaction (qPCR) using the SYBR Green method.
Significant differences between cell viability and gene expression levels were determined (Prism 5.0 software) using one-way anal-
yses of variance (ANOVA) test.
Results: We reported that SEB could effectively down-regulate smad2/3 expression in glioblastoma cells at concentrations as quan-
tity as 1 µg/mL and 2 µg/mL (P < 0.05 and P < 0.01, respectively). The SEB concentrations effective at regulating smad2/3 expression
were correlated with those used to inhibit the proliferation of glioblastoma cells. Our results also showed that SEB was able to de-
crease smad2/3 expression at the mRNA level in a concentration- and time-dependent manner.
Conclusions: We suggested that SEB could represent an agent that can significantly decrease smad2/3 expression in glioblastoma
cells, leading to moderate TGF-β growth signaling and the reduction of tumor cell proliferation.
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1. Background
Glioblastoma, a malignant type of brain cancer, is one
of the most aggressive human cancers in adults. This can-
cer is usually considered to have a high degree of mor-
bidity and mortality (1, 2). Despite the progress that has
been made in understanding the molecular mechanisms
involved in the genesis and progression of glioblastoma,
prognosis and treatment are refractory to radiotherapy
and chemotherapy. These characteristics make this tumor
type an excellent area for cancer research and therapeu-
tic approaches (2). On the other hand, it is well known
that the aberration of the growth factors signaling path-
ways could play an important role in tumor initiation, pro-
gression and metastasis in glioblastoma (3, 4). Transform-
ing growth factor beta (TGF-β) has been identified as a key
growth factor that triggers various biological processes,
such as proliferation, differentiation and programmed cell
death. Studies have shown that cell signaling at the late
stage of some cancers promote tumor development, pro-
gression and metastasis. Dysregulation of this pathway re-
sults in various cancers, including glioblastoma (4), colon,
breast and prostate cancer (5, 6).
The TGF-β signaling pathway is important in brain tu-
mor cell homeostasis and supports glioblastoma cell pro-
liferation and migration (4-6). This fact has prompted the
development of anticancer strategies based on inhibition
of this signaling pathway (5, 6). However, due to the com-
plexity of the TGF-β signaling pathway, it is crucial to un-
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derstand how TGF-β inhibition affects tumor biology in or-
der to assess and improve the therapeutic potential and
clinical testing of anti-TGF-β compounds. TGF-β molecule
binds to heterodimeric receptor complexes of transmem-
brane serine/threonine kinases called type I and type II
receptors (TGβRI and TGβRII). Cell signaling is triggered
through the interaction of the TGF-β and the following
TGβRII to activate TGβRI. Activated TGβRI then results in
the recruitment and phosphorylation of a family of tran-
scription factors or signal transducers termed smad fac-
tors.
A complex of phosphorylated smad2 and smad3 com-
ponents associates with smad4 and translocates to the nu-
cleus, where the transcription of downstream target genes
is activated (7, 8). The regulation of signaling components’
expression and function should include mechanisms that
allow for a diversity of events depending on cell and tis-
sue contexts (8, 9). Several reports imply that the target-
ing of a TGF-β signaling pathway at the late stage of car-
cinogenesis could be a helpful tool for the treatment of hu-
man cancers, such as glioblastoma, colorectal and breast
cancer. Thereby, repressing the TGF-β signal transducer
expression could provide a rational therapeutic strategy
for the treatment of these cancers (8-10). For hundreds of
years, it has been recorded that certain infectious diseases
could exert a beneficial therapeutic effect upon some ma-
lignancies (11, 12).
Using bacteria and their components in cancer therapy
has been executed in different fields, including utilizing,
as a vector for gene therapy, carriers of tumoricidal agents
and bacterial toxins as a tumor repressor via binding to
tumor-surface antigens. One unique bacterial factor that
would suggest a protective role in carcinogenesis or cause
the remission of a cancer is a toxin (13-15). Evidence is grow-
ing that certain types of bacterial toxins have emerged as
being promising in the prevention or cure of cancers. This
fact inspired the development of the earliest toxin-based
cancer therapies (11-13). Some bacteria are well known for
their ability to secrete enterotoxins changing cellular sig-
naling processes that control proliferation, apoptosis and
differentiation in carcinogenesis (16-19).
Regarding the basic function of bacterial enterotoxins
in tumor regression, it is rational to hypothesize that anti-
cancer properties may partially be related to their alter-
ation of the cell signaling genes involved in cancer devel-
opment and progression. However, modulation of a dis-
tinct signaling pathway that would explain the possible
inhibitory action of Staphylococcal enterotoxins on can-
cers, in particular glioblastoma, has not been elucidated.
Staphylococcal enterotoxins are a family of structurally re-
lated proteins produced by Staphylococcus aureus, termed
superantigens. These proteins bind to major histocom-
patibility complex (MHC)-II molecules on cells and induce
T lymphocytes clonally (20, 21). It has been revealed that
Staphylococcus aureus enterotoxin B (SEB) may feature anti-
cancer and anti-metastatic advantages due to their ability
to modify cell immunity processes as well as cancer cell sig-
naling pathways (20). These attractive characteristics stim-
ulated us to research whether this enterotoxin may reduce
the proliferation of glioblastoma cells. Because this bacte-
rial enterotoxin has been previously experienced for can-
cer treatment (20-23), we hypothesized that the anti-cancer
properties of the toxin could partially stem from changes
in growth signaling pathways.
2. Objectives
Our aim was to investigate the human glioblastoma
growth inhibitory effect of SEB through the manipulation
of TGF-β signaling pathway transducers, smad2/3, in vitro.
The study was designed to provide insight into the molec-
ular mechanism of SEB in human glioblastoma cell sig-
naling pathways, emphasizing the potential novel idea in
toxin-based cancer therapy.
3. Materials andMethods
3.1. Cell Culture
A human primary glioblastoma cell line with a patho-
logic differentiation grade of original tumors II, U87, was
selected for examining the effect of SEB on TGF-β signal-
ing transducers. The cell line was obtained from the na-
tional cell bank of Iran (NCBI) affiliated with Pasteur Insti-
tute (Tehran, Iran) and was grown in an RPMI-1640 medium
(Gibco; Germany) containing 25 mM D-glucose, 4 mM L-
glutamine and 1 mM sodium pyruvate and supplemented
with 5% (v/v) heat-inactivated fetal bovine serum (FBS)
(Gibco; Germany), 2 mM glutamax (Gibco; Germany), 100
U/mL penicillin, 100 µg/mL streptomycin and 250 ng/mL
amphoterycin (Gibco; Germany) in a culture flask that was
25 cm2 (SPL Life Sciences; South Korea). The cells were kept
at 37°C in a humidified 95% atmosphere in a 5% CO2 at-
mosphere incubator designated as the culture in a steady-
state condition. The cell viability was assessed using a
trypan blue exclusion test and was routinely found in all
flasks containing more than 95% viable cells.
3.2. Staphylococcus aureus Enterotoxin B (SEB) Preparation
Staphylococcus aureus enterotoxin B was purchased
from Sigma Aldrich (Belgium) and was dissolved in dis-
tilled water according to the manufacturer’s instruction.
The enterotoxin was prepared as stock solutions of 20
µg/mL and kept at -20°C until use.
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3.3. Methyl Thiazolyltetrazolium (MTT) Assay
To quantify cell proliferation, the in vitro growth in-
hibitory effect of SEB was measured using the MTT assay
(Roche Applied Science; Germany). Briefly, monolayer cul-
tures were trypsinized in the exponential growth phase,
and viable cell counts were assessed using trypan blue ex-
clusion. Then, cells were seeded in 96 well flat-bottom mi-
cro titration plates (SPL Life Sciences; South Korea) at a den-
sity of 105 cells/well (200 µL media/well). After 24 hours,
once the cells reached ~ 85% confluence, they were treated
with different concentrations of SEB (0.5 µg/mL, 1 µg/mL
and 2µg/mL). Following 24 hours drug exposure, for the re-
covery period, the cells were washed two times with fresh
and free-FBS medium, and the culture continued (Figure
1). Subsequently, a fresh medium containing FBS was re-
placed for the removal of unbound SEB. In all in vitro ex-
periments, control cells were incubated with distilled wa-
ter (DW) alone (with a final volume of 5 µL). The complete
medium was replaced with 100 µL MTT after 24, 48, and 72
hours incubation periods. The cells were incubated for 3
hours at 37°C, and then 100 µL dymethyl sulfoxide (DMSO)
was added to each well. Finally, the optical density (OD) was
measured at a wavelength of 570 nm with background sub-
traction at 630 nm using a spectrophotometric micro plate
reader (BioTekElx. 808). The cell viability was calculated us-
ing the following formula:
(1)Cell Viability (%) =
ODtoxin exposure
ODcontrol
× 100
3.4. Total Ribonucleic Acid (RNA) Extraction From Cells
The cultured U87 cells, at the mentioned time points
either before or after treatment with SEB, were subjected
to total RNA extraction. Total cellular RNA was extracted
using trizol reagent (Invitrogen; Germany) according to
the manufacturer’s instructions. Extracted total RNA was
stored at -80°C until use.
3.5. Gene Expression Analysis by Reverse-Transcription (RT)
Real-Time Polymerase Chain Reaction (PCR)
smad2/3 gene expression at the mRNA level was an-
alyzed via SYBR Green quantitative real-time polymerase
chain reactions (qPCR) using the specific forward and re-
verse primers for the genes (Table 1). The GAPDH gene was
used as an endogenous (internal) control, and the data
were normalized to the expression level of this housekeep-
ing gene. Our protocol included two steps: reverse tran-
scription (RT) and real-time PCR. Briefly, RNA was tran-
scripted to complementary deoxyribonucleic acid (cDNA)
using the oligodT procedure. Briefly, the cDNA was syn-
thesized using total RNA and specific primers in a reverse
transcription reaction. This reaction was performed in a
volume of 10 µL containing 1 µL total RNA, 1 µL of 0.5 mM
oligodT RT primer, 1 µL of 10 mM dNTP, 1 µL RT enzyme and
6 µL reaction buffer.
The reaction was incubated at 42°C for 60 minutes and
then terminated by heating at 85°C for 5 minutes. Sub-
sequently, diluted cDNAs were amplified in a 20 µL reac-
tion containing SYBER Green master mix, forward and re-
verse Sma2/3 specific primers (each 1 µL) and diethylpy-
rocarbonate (DEPC)-treated distilled water by 35 cycles of
PCR amplification under the following conditions: dena-
turing at 95°C for 1 minute, annealing at 56°C for 1 minute,
and extension at 72°C for 1 minute. Real-time PCR was car-
ried out on a Bio Rad CFX96 Real-Time PCR system. All
of the reactions were performed in triplicate. The speci-
ficity of primers was verified by observing a single peak
dissociation curve for each run. The threshold cycle (CT)
was defined as the fractional cycle number at which the
[U+FB02]uorescence passed the fixed threshold. CT val-
ues were converted into total copy numbers using a stan-
dard curve. The absence of contamination was verified us-
ing non-template controls. PCR products were also visual-
ized by electrophoresis on a 2% agarose gel stained by gel
red (Figure 2).
Table 1. The Specific Primer Sequences Used in This Study
Target Genes Primers Sequences (5′→3′) PCR Product Size, bp
Smad2 480
Forward TCAAGCTTGAGTGTAAACCCTTACCACTATC
Reverse TAGCGGCCGCGAAAGCTATGATTAACAG48GGG
Smad3 340
Forward TCAAGCTTGAACACCAGTTCTACCTCCTG
Reverse TAGCGGCCGCGAAATGTCTCCCCGACGCGCTG
GAPDH 190
Forward CGTTCCCAAAGTCCTCCTGTTTC
Reverse TTTTTTTCCGCAGCCGCCTG
Real-time PCR data were analyzed using the 2-∆∆ct
method via GraphPad Prism 5.0 software. A compari-
son of the cell viability and gene expression means was
completed by analysis of variance (ANOVA) and Turkey’s
posttest. P values less than 0.05 were considered to indi-
cate statistically significant differences between data sets.
Jundishapur J Microbiol. 2016; 9(5):e27297. 3
Akbari A et al.
Figure 1. U87 Cell Culture and Treatment With SEB
A U87 cell was cultured and treated with no (A); with distilled water as a control (B); with 0.5µg/mL (C); 1µg/mL (D); and 2 µg/mL (E) concentrations of SEB. The cells were
cultured as a monolayer in microtitration plates and evaluated microscopically after 48 hours of exposure.
Figure 2. Gel Electrophoresis of PCR Products
Smad 2/3genes and the GAPDH housekeeping gene (as an internal control) PCR prod-
uct were subjected to electrophoresis on gel agarose 2% stained with gel red.
4. Results
4.1. SEB Can Reduce the Proliferation of Human Primary
Glioblastoma Cell Line U87
In order to examine the anti-proliferative activities of
SEB, the growth inhibitory effect was evaluated by MMT
assay in different concentrations and times. Our data
showed that SEB could significantly decrease U87 cell via-
bility after 48 hours in concentrations of 1 and 2µg/mL (P <
0.05, P < 0.01, respectively). We concluded that SEB exerts
its growth inhibitory effects in a concentration and time-
dependant manner. On the whole, the findings revealed
that SEB was the effective inhibitor of human glioblastoma
cell proliferation (Figure 3).
4.2. SEB Could Down-Regulate smad2/3 Expression in U87 Cell
Line
The expression level of TGF-β signal transducers,
smad2/3, was evaluated by real-time PCR. Our results
showed that SEB at concentrations of 1 µg/mL and 2 µg/mL
could reduce smad2/3 expression in the human glioblas-
toma U87 cell line. SEB could significantly reduce the ex-
pression level of smad2 with a concentration of 2 µg/mL
in 72 hours (P < 0.01). However, the expression level of
smad3 was significantly reduced by SEB treatment either
at concentrations of 2 µg/mL in 48 hours (P < 0.01) or 1
µg/mL and 2 µg/mL in 72 hours (P < 0.01 and P < 0.01, re-
spectively). The results revealed that SEB reduces smad2/3
expression in a dose- and time-dependent manner (Figure
4). Because SEB at high concentrations also exerts an in-
hibitory effect on U87 cells, it was presumed that this ob-
servable phenomenon could at least partially be a conse-
quence of the down-regulated expression of TGF-β signal-
ing components.
Overall, we predicted that SEB, as a potent inhibitor of
human glioblastoma cell proliferation, would regulate the
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Figure 3. Cell Viability of U87 After SEB Treatment
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A, cell viability of U87 after 24 hours of treatment; B, cell viability of U87 after 48 hours
of treatment; C, cell viability of U87 after 72 hours of treatment. MTT assay results
showed that SEB treatment at different times could significantly induce growth in-
hibitory effects on U87 cells in concentrations of 1µg/mL and 2µg/mL.
gene expression of key transducers that control TGF-β sig-
naling in cancerous cells. Interestingly, the SEB concen-
trations effective at inhibiting the expression of smad2/3
Figure 4. Relative smad2/3 Gene Expression Normalized by Housekeeping Gene
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A, smad2; B, smad3.U87 cells after 48 hours of treatment with concentrations of 1
µg/mL and 2 µg/mL of SEB showed a significant reduction in smad2 and smad2/33
gene expression.
correlated with those used to decrease the proliferation of
U87 cells. According to our data, it is thought the down-
regulation of smad2/3 in the presence of SEB could precede
the inhibitory effects of SEB on cell proliferation. How-
ever, this idea that SEB could cause a reduction in hu-
man glioblastoma proliferation through smad2/3 down-
regulation needs to be further evaluated.
5. Discussion
Nowadays, malignancies, including brain cancers, are
considered an excellent area for research and therapy be-
cause of their high mortality rate (1-3). With regard to
glioblastoma, it is well known that aberration in genes that
encode transforming growth factor-beta (TGF-β) signaling
components can contribute to carcinogenesis (4, 6). This
signaling pathway can control many cellular functions, in-
cluding cell proliferation, apoptosis and migration as well
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as tumor initiation, progression and metastasis (6, 7), mak-
ing it as a suitable target in cancer therapy (7, 8). Bacte-
rial toxins are a specific group of components that are now
widely studied for their anticancer activities. A number
of these toxins are in clinical development, which gives us
hope for their pharmacological use as growth inhibitory
agents in cancer treatment (12-14). These biomolecules can
kill cells or alter cellular processes that control prolifera-
tion, apoptosis and differentiation. These attractive char-
acteristics have stimulated research into whether these
may be used as anticancer agents (12, 13, 15).
In spite of reported in vitro and in vivo results, in order
to make it the right therapeutic approach in cancer treat-
ment, more investigations on cellular mechanism target-
ing by bacteria are required. In line with this, the cancer-
promoting signaling pathways manipulated by bacterial
toxins have been evaluated in various studies (17, 19). SEB
belongs to super antigens family, whose functional activ-
ity is based on binding to both the β-chain of the T cell
receptor (TcR) and the major histocompatibility complex
(MHC) class II dimer (20). It has been suggested that SEB
could exert anti-cancer and anti-metastatic effects due to
their ability to modify cancer signaling pathways and their
cell immunity (21, 22). Therefore, we hypothesized that the
anti-cancer functions of the enterotoxin could be partially
caused by changes in cancer signaling pathways.
According to one previous study on glioblastoma cell
lines and normal brain tissues (22), it has been revealed
that the U87 and U343 tumor cell lines are characterized
by the increased expression of the major histocompati-
bility complex (MHC)-I and -II molecules. Because the ex-
istence of functionally active SEB-binding structures on
U87 cells is suggested to mediate cellular modulations
(22), we selected the U87 cell line as a promising target
cell. We predicted that SEB, the potent inhibitor of hu-
man glioblastoma cell proliferation, could moderate the
expression of key transducer genes that control TGF-β sig-
naling in cancer cells. This study was designed to provide
insight into the molecular mechanisms of SEB in cell sig-
naling pathways, emphasizing a potential novel idea in
the cancer therapy of glioblastoma and other malignan-
cies involving the TGF-β signaling pathway. Through the
treatment of U87 cells with SEB, we determined an inhibi-
tion of smad2/3 gene expression in U87 cells in a time- and
concentration-dependent manner. The inhibitory action
of SEB on smad2/3 expression took place at concentrations
of either 1 µg/mL or 2 µg/mL (P < 0.05).
It was presumed that this observable phenomenon
could at least partially be a consequence of the down-
regulated expression of TGF-β signaling components. In
addition, SEB was significantly more effective at reducing
smad3 gene expression in comparison to smad2. We also
revealed that after 48 hours of treatment at high concen-
trations (1 µg/mL and 2 µg/mL), SEB exerts an inhibitory
effect on U87 cell proliferation (P < 0.05 and P < 0.01, re-
spectively). The SEB concentrations effective in decreas-
ing smad2/3 expression correlated with those used to in-
hibit the proliferation of U87 cells. According to our data,
it is thought that the down-regulation of smad2/3 could
precede the inhibitory effects of SEB on cell proliferation.
However, further evaluations are needed to confirm this
claim. In total, our findings are consistent with those from
studies that showed SEB exerts anti-angiogenic effects (21,
22). In these studies, SEB was discovered to be effective in
apoptosis and in harmonizing cancer cell proliferation. In
line with our data, some researchers have shown that SEB
could induce the Fas/Fas ligand-mediated cytolysis of tar-
get cells. They supposed that the Fas/Fas ligand could be a
key mediator for SEB-mediated cell death (24).
In this regard, it should be noted that TGF-β also
activates other downstream signaling pathways, includ-
ing Rho GTPases, the extra-cellular signaling-regulated
kinases (ERK), c-Jun NH2-terminals kinase (JNK) and
phosphatidylinositol-3;kinase (PI3K) (6-8). It is likely
that these pathways are also affected by the enterotoxin.
Therefore, this idea that SEB could represent a complete
reduction in human glioblastoma proliferation only by
smad2/3 down-regulation needs to be comprehensively
examined. In addition, it has recently been reported that
the anthrax toxin (a dangerous bacterial toxin secreted by
Bacillus anthraces) inhibits the growth of ras-transformed
cancerous cells by disturbing the mitogene-activated
protein kinases (MAPKs) signaling pathway (23). Thus, it
has been supposed that the agent could be used against
cancer cells in which MAPKs are activated by oncogenic
proteins.
These features ensure the selective damage of tumors
yet at a very low dosage (24). Furthermore, other inves-
tigations imply that some bacterial toxins could be used
in targeted-cancer therapy, and others synergistically pro-
mote the activity of the anticancer drugs (25, 26). There-
fore, it is strongly proposed to complete additional sup-
plementary studies to examine the synergistic activity of
the enterotoxin with routine anticancer drugs. Our results
suggested SEB could be used against cancer cells undergo-
ing TGF-β signaling dysregulation or likely over-activation
by other oncogenic proteins. Although SEB is proposed to
be an attractive bio-molecule for treating cancers, a major
problem is its toxicity at the dose required for therapeutic
efficacy. Moreover, insufficient experimental evidence ex-
ists to justify the conclusion that the SEB has therapeutic
value in TGβRI/II positive cancer cells.
As a final point, the identification of the molecular
mechanisms involved in bio-toxins’ functions could pro-
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vide novel insight into immunotoxin-based cancer ther-
apy. Further investigation and developments in these stud-
ies will add a new dimension to cancer treatment. The
continued examination of these molecular aspects will
bring research ever closer to the more effective thera-
pies, such as the immunotoxin-based therapy of malignan-
cies. Nonetheless, the successful translation of these ap-
proaches into scientific practice will depend on the out-
come of intended clinical trials.
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